AbbVie lifts 2025 guidance after beating Q1 estimates
Overview AbbVie started 2025 with strong momentum, reporting revenue and adjusted earnings ahead of expectations, driven by robust growth in Immunology and Neuroscience portfolios. CEO Robert A. Michael emphasized the company’s positive trajectory: “AbbVie’s first-quarter results were well ahead of our expectations and reflect an excellent start to the year. The fundamentals of our business…
